Collaborative Arrangements and Licensing Agreements (Tables)

12 Months Ended

Dec. 31, 2021

Biogen [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the years ended December 31, 2021, 2020 and 2019, we earned the following revenue from our relationship with Biogen (in millions, except percentage amounts):

	Year Ended December 31,
	2021			2020			2019
SPINRAZA royalties (commercial revenue)	$	267.8		$	286.6		$	293.0
R&D revenue		161.0			122.0			180.6
Total revenue from our relationship with Biogen	$	428.8		$	408.6		$	473.6
Percentage of total revenue		53	%		56	%		42	%

AstraZeneca [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the years ended December 31, 2021, 2020 and 2019, we earned the following revenue from our relationship with AstraZeneca (in millions, except percentage amounts):

	Year Ended December 31,
	2021			2020			2019
R&D revenue	$	254.6		$	88.0		$	28.1
Percentage of total revenue		31	%		12	%		3	%

Bayer [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the years ended December 31, 2021, 2020 and 2019, we earned the following revenue from our relationship with Bayer (in millions, except percentage amounts):

	Year Ended December 31,
	2021			2020			2019
R&D revenue	$	1.1		$	3.2		$	14.3
Percentage of total revenue		0	%		0	%		1	%

GSK [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the years ended December 31, 2021, 2020 and 2019, we earned the following revenue from our relationship with GSK (in millions, except percentage amounts):

	Year Ended December 31,
	2021		2020			2019
R&D revenue	$	—	$	0.2		$	25.4
Percentage of total revenue		—		0	%		2	%

Novartis [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the years ended December 31, 2021, 2020 and 2019, we earned the following revenue from our relationship with Novartis (in millions, except percentage amounts):

	Year Ended December 31,
	2021			2020			2019
R&D revenue	$	25.5		$	1.0		$	187.4
Percentage of total revenue		3	%		0	%		17	%

Roche [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the years ended December 31, 2021, 2020 and 2019, we earned the following revenue from our relationship with Roche (in millions, except percentage amounts):

	Year Ended December 31,
	2021			2020			2019
R&D revenue	$	17.2		$	5.9		$	57.0
Percentage of total revenue		2	%		1	%		5	%

Alnylam [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the years ended December 31, 2021, 2020 and 2019, we earned the following revenue from our relationship with Alnylam (in millions, except percentage amounts):

	Year Ended December 31,
	2021		2020			2019
R&D revenue	$	—	$	47.9		$	24.1
Percentage of total revenue		—		7	%		2	%